Why Artivion (AORT) Stock Is Down Today
Artivion (AORT) stock fell 2.1% after a proposed 2027 federal budget outlined significant spending cuts for health agencies, including a $5 billion reduction for the National Institutes of Health (NIH). Despite the unlikelihood of full approval, the proposal introduced uncertainty for the medical research sector. The stock is down 24.7% since the beginning of the year and 29.7% below its 52-week high, but investors who bought 5 years ago would have seen their investment grow by 48%.
Artivion Inc (AORT) Trading Down 3.24% on Apr 6
Artivion Inc (AORT) saw its shares drop by 3.24% on April 6, hitting an intraday low of $33.00 before settling at $33.06. This places the stock 31.48% below its 52-week high and 50.49% above its 52-week low. Wall Street analysts provide an average price target of $51.43, suggesting a 55.55% upside, with a consensus "Outperform" rating, while GuruFocus estimates a one-year GF Value of $27.54, implying a 16.7% downside.
Should Artivion’s Q4 Revenue Miss Amid Strong Product Growth Require Action From AORT Investors?
Artivion's Q4 results showed a 19.2% year-on-year revenue increase, propelled by strong growth in stent grafts, On-X products, and preservation services, yet fell slightly short of analyst expectations by 0.8%. Despite this miss, the company demonstrated solid full-year 2025 adjusted revenue and EBITDA growth. The article examines whether this slight quarterly revenue miss, alongside robust product growth and positive clinical trial data, impacts the long-term investment narrative, which relies on converting clinical outcomes into broader commercial use.
Artivion, Inc. (AORT) stock price, news, quote and history
Artivion, Inc. (AORT) is a medical device and implantable human tissue manufacturer with a market capitalization of $1.636 billion. The article provides current stock performance data, historical information, financial highlights, and analyst insights, including price targets and recommendations. The company designs and distributes a variety of cardiovascular and other medical devices globally.
Holloway Jean F, Artivion SVP, sells $83k in shares
Jean F Holloway, SVP and General Counsel at Artivion Inc., sold 2,183 shares of the company's common stock for a total of $83,008. The sale was executed to cover tax withholding obligations related to restricted stock units rather than a discretionary transaction. Following this, Holloway directly owns 170,105 shares, while InvestingPro analysis suggests the stock is overvalued despite the company's profitability and $1.85 billion market capitalization.
Artivion Inc Com (AORT) Stock Price | Live Quotes & Charts | NYSE
This page provides live quotes and charts for Artivion Inc Com (AORT) stock, showing its current price as $34.17 with no change. It also mentions that there are no analyst ratings or earnings information currently available for AORT. The page encourages users to sign up for free trade alerts and join a virtual trading conference.
EDGAR Filing Documents for 0001999371-26-007510
This SEC EDGAR filing details a DEF 14A form submitted by ARTIVION, INC. on April 1, 2026. The filing includes a definitive proxy statement and related interactive data documents, with a period of report ending May 12, 2026. It provides comprehensive information on the company's proxy materials, including various graphic files and XBRL data.
Artivion (AORT) details 2026 virtual meeting, director slate and Say on Pay
Artivion, Inc. (AORT) announced details for its virtual-only 2026 Annual Shareholder Meeting scheduled for May 12, 2026, at 9:00 a.m. ET. Shareholders as of March 16, 2026, will vote on the election of nine directors, the advisory "Say on Pay" resolution for executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for 2026. The Board of Directors recommends voting in favor of all proposals, highlighting that non-employee directors are independent and executive compensation aligns with company performance.
Artivion (NYSE:AORT) Shares Down 6.6% - What's Next?
Artivion (NYSE:AORT) shares dropped 6.6% on Wednesday, trading at $34.1850. Despite beating earnings expectations with $0.17 EPS and a 19.2% revenue increase, the stock has a high P/E of 169.9. Wall Street maintains a "Moderate Buy" consensus with an average target of $50.47, though recent analyst actions have been mixed, and insider selling has been noted this quarter.
Artivion, Inc. (CYL.F) stock price, news, quote and history
This article provides detailed financial information and recent performance data for Artivion, Inc. (CYL.F), formerly known as CryoLife, Inc., a medical device and implantable human tissue company. It includes stock quotes, historical data, an overview of its products, earnings trends, and financial highlights such as profitability and balance sheet figures. The report also allows for comparison with other companies in the medical devices industry.
Is It Too Late To Reassess Artivion (AORT) After Its Strong Multi Year Share Price Run?
Artivion (AORT) has seen significant share price appreciation over the past three years, with a 176.1% return, though it has pulled back recently. Despite its strong performance, Simply Wall St's discounted cash flow analysis suggests the stock is currently 121.3% overvalued at around US$35 per share, with an intrinsic value of $15.95. The article also notes that Artivion's Price-to-Sales ratio of 3.83x is above both industry averages and its proprietary "Fair Ratio," further indicating overvaluation.
Tudor Investment Corp ET AL Cuts Position in Artivion, Inc. $AORT
Tudor Investment Corp ET AL significantly reduced its stake in Artivion, Inc. ($AORT) by 36.7% in Q3, selling 39,388 shares and retaining 68,021 shares valued at approximately $2.88 million. Despite this, other institutions like Voloridge Investment Management LLC and Wasatch Advisors LP increased their holdings. Insider selling also occurred, totaling 133,043 shares, while analysts maintain a "Moderate Buy" rating with an average target price of $50.47 for Artivion.
Artivion, Inc. (NYSE:AORT) Receives Consensus Rating of "Moderate Buy" from Analysts
Artivion, Inc. (NYSE:AORT) has received a consensus "Moderate Buy" rating from analysts, with six out of eight recommending a buy and an average 12-month target price of $50.47. The company recently exceeded earnings expectations, reporting an EPS of $0.17 against an estimated $0.14, and revenue of $118.3 million, a 19.2% increase year-over-year. Despite notable insider selling totaling approximately $4.98 million, insiders still retain a 7.60% ownership stake in the company.
Vanguard reports 0 AORT shares after internal realignment (NASDAQ: AORT)
The Vanguard Group filed an Amendment No. 6 to its Schedule 13G/A for Artivion Inc (NASDAQ: AORT), reporting zero shares beneficially owned and 0% of the class. This change reflects an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries will report their holdings separately, citing SEC Release No. 34-39538. The filing, signed by Ashley Grim, Head of Global Fund Administration, indicates that Vanguard no longer has or is deemed to have beneficial ownership over securities now reported by these disaggregated entities.
Stifel Maintains Artivion (AORT) Buy Recommendation
Stifel has reiterated its Buy recommendation for Artivion (AORT) and maintained a $27.00 price target. This continued positive outlook from the analyst firm suggests confidence in the company's future performance.
AORT Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Artivion Inc (AORT). Based on 11 technical signals, the consensus is a "Strong Sell," with the stock currently trading at $35.31. Key indicators like MACD and various simple moving averages also signal a "Sell," with the stock trading below its 200-day moving average.
Artivion, Inc. Forms Death Cross, Signaling Potential Bearish Trend Ahead
Artivion, Inc. has formed a "Death Cross," indicating a potential bearish trend, despite a strong 51.2% annual performance. This technical event, where the short-term moving average crosses below the long-term, suggests a shift in market sentiment. While daily moving averages and some indicators are bearish, the monthly MACD remains bullish, presenting a mixed outlook for investors.
Juniper Investment Company LLC Sells 760,257 Shares of Artivion, Inc. $AORT
Juniper Investment Company LLC significantly reduced its stake in Artivion, Inc. (NYSE:AORT) by 36.3%, selling 760,257 shares and now owning 1,333,692 shares valued at $56.47 million. Despite insider selling and a high P/E ratio, other institutional investors like Vanguard and Two Sigma increased their holdings, and analysts maintain a "Moderate Buy" rating with an average target price of $50.47. Artivion recently exceeded earnings and revenue expectations.
Fred Alger Management LLC Sells 33,709 Shares of Artivion, Inc. $AORT
Fred Alger Management LLC reduced its stake in Artivion, Inc. by 2.5%, selling 33,709 shares, but still holds 1,317,250 shares valued at approximately $55.8 million, representing 2.78% of the company. Other institutional investors like Vanguard and Two Sigma increased their positions, while company insiders sold 133,043 shares. Analysts currently rate Artivion as a "Moderate Buy" with an average target price of $50.47, following the company's recent EPS beat and 19.2% year-over-year revenue growth.
How Investors May Respond To Artivion (AORT) Analyst Optimism Around NEXUS Stent Graft Trial Results
Analysts are optimistic about Artivion (AORT) following positive one-year trial data for its NEXUS stent graft system, highlighting strong sealing and low endoleak rates. This optimism, coupled with physician interest, suggests that Artivion’s aortic pipeline could bolster its market position upon FDA approval. However, investors are cautioned to consider regulatory delays and development costs as potential risks, despite the company's improved financial footing in 2025.
How Investors May Respond To Artivion (AORT) Analyst Optimism Around NEXUS Stent Graft Trial Results
Analysts are optimistic about Artivion's NEXUS stent graft system after positive one-year trial data, signaling potential FDA approval and market adoption. However, investors should balance this optimism with the risks of regulatory delays and development costs, despite Artivion's improved financial footing. The company's future growth hinges on the successful commercialization of its aortic disease pipeline.
Kennedy Capital Management LLC Increases Stock Holdings in Artivion, Inc. $AORT
Kennedy Capital Management LLC significantly increased its stake in Artivion, Inc. by 19.0% in Q3, now holding 437,792 shares valued at approximately $18.54 million. While institutional ownership is high and analysts generally rate the stock as a "Moderate Buy," company insiders have been net sellers, divesting shares worth nearly $5 million in the last 90 days. Artivion's stock performance shows a 50-day moving average of $40.27 and a 200-day moving average of $42.64, with the company beating earnings estimates in its last report.
Assessing Artivion (AORT) Valuation After Positive Analyst Views On Aortic Pipeline And NEXUS Trial Results
Recent analyst reports have highlighted Artivion's (AORT) aortic disease pipeline, particularly the NEXUS stent graft system's positive one-year trial results. Despite recent share price fluctuations, Artivion's long-term momentum remains strong, driven by pipeline updates and favorable analyst commentary. The company's valuation presents a mixed picture, with a fair value suggesting it is undervalued, but its price-to-sales ratio indicating higher valuation risk compared to its industry and peers.
Stifel Remains a Buy on Artivion (AROT)
Stifel analyst John McAulay reiterated a Buy rating on Artivion (AROT) with a $55 price target, citing the company's strong aortic disease pipeline. The key driver for this optimistic outlook is the NEXUS stent graft system, which showed promising one-year results from its TRIOMPHE pivotal trial, indicating strong sealing and low endoleak rates. The analyst also noted positive feedback from physicians experienced with NEXUS implants, who intend to adopt the system post-FDA approval.
Heart-focused medical device company makes $20.3M real estate purchase
Artivion Inc., a medical device company based in Atlanta, has completed a $20.3 million real estate acquisition in Austin, Texas. The purchase involves approximately 160,000 square feet of space, intended to accommodate the company's expansion needs. This move highlights ongoing growth and investment in commercial real estate within the Austin area.
Artivion (AORT) EVP Lance Berry gets stock award, sells shares for taxes
Artivion, Inc.'s EVP Lance A. Berry received a grant of 40,874 common shares on March 2, 2026, as part of performance stock units awarded in February 2025. Subsequently, on March 3, 2026, he sold 6,316 shares at an average price of $37.7756 to cover tax withholding obligations arising from the vesting. This "sell to cover" transaction was not a discretionary trade, and following these actions, Berry directly holds 210,827 shares of Artivion common stock.
GW&K Investment Management LLC Sells 135,784 Shares of Artivion, Inc. $AORT
GW&K Investment Management LLC reduced its stake in Artivion, Inc. (NYSE:AORT) by 13.9% in the third quarter, selling 135,784 shares and holding 843,907 shares worth $35.73 million. Despite this sale, other institutional investors like Vanguard Group Inc. and JPMorgan Chase & Co. increased their positions in Artivion, which recently reported stronger-than-expected earnings and has a "Moderate Buy" analyst rating. The article also notes recent insider selling by Artivion executives, including CEO James P. Mackin.
Marshall Stanton Implements A Sell Strategy: Offloads $81K In Artivion Stock
Marshall Stanton, SVP at Artivion (NYSE: AORT), recently sold 2,149 shares of the company's stock for a total transaction value of $81,179. This insider sale was disclosed in an SEC filing on March 4, with Artivion shares trading down slightly at the time of the article's writing. The article also provides a business overview of Artivion, its financial performance, and valuation metrics, emphasizing that insider sells don't always indicate a bearish outlook.
Artivion (AORT) SVP, General Counsel reports stock award and tax-cover sales
Artivion (AORT) SVP and General Counsel, Jean F. Holloway, reported receiving 27,795 shares of common stock from a performance stock unit award. Following this, she sold 12,805 shares in two transactions on March 3rd and 4th, 2026, at average prices of $37.7756 and $38.00, respectively. These sales were non-discretionary and exclusively conducted to cover tax withholding obligations associated with the stock award.
Insider Selling: Artivion (NYSE:AORT) SVP Sells 3,843 Shares of Stock
Artivion (NYSE:AORT) Senior Vice President Jean Holloway sold 3,843 shares of the company's stock on March 3rd for approximately $145,189, reducing her stake by 1.94%. This sale was part of a larger trend of several senior insiders selling shares between March 2-4, which may negatively impact investor sentiment despite the company's recent earnings beat and analyst "Moderate Buy" rating. The stock's current trading price is $38.41, with a market capitalization of $1.84 billion.
Artivion CEO Mackin sells $675k in shares
Artivion CEO James P. Mackin sold 17,887 shares of common stock for $675,692 to cover tax withholding obligations related to vested performance stock units. This transaction follows Mackin's acquisition of 116,948 shares for $0 as part of a vesting schedule. The company recently reported strong Q4 2025 financial results with higher-than-expected EPS and increased adjusted revenues.
Artivion EVP Berry sells $238k in shares after stock grant
Artivion's EVP, COO, CFO & Treasurer, Lance A. Berry, sold 6,316 shares of common stock for $238,590 to cover tax obligations arising from a stock grant. This transaction occurred after Berry received a grant of 40,874 shares, which were part of performance stock units. The company recently reported strong Q4 2025 earnings, exceeding EPS expectations, and analysts like Canaccord Genuity have adjusted price targets while maintaining a Buy rating.
Artivion (AORT) CCO Davis sells $172k in shares to cover tax obligations
Artivion (AORT) Chief Commercial Officer John E. Davis sold 4,573 shares of common stock for $172,747 to cover tax obligations due to vesting performance stock units. This transaction followed his acquisition of 28,845 shares from similar stock units. Artivion recently reported strong Q4 2025 financial results, exceeding EPS expectations, and its stock has shown significant growth.
Artivion (AORT) CCO receives stock units, sells shares to cover taxes
Artivion, Inc.'s Chief Commercial Officer, John E. Davis, reported acquiring 28,845 shares from the vesting of performance stock units and subsequently selling 4,573 shares at an average price of $37.7756. This sale was a non-discretionary "sell to cover" transaction to satisfy tax withholding obligations. Following these transactions, Davis directly holds 230,794 shares of Artivion common stock.
Artivion (AORT) CAO executes 641-share tax sell-to-cover transaction
Artivion, Inc.'s VP and Chief Accounting Officer, Amy Horton, sold 641 shares of common stock at approximately $38.02 per share. This transaction was a non-discretionary "sell-to-cover" sale to fulfill tax withholding obligations upon the vesting of restricted stock units. Following the sale, Ms. Horton directly holds 132,514 shares of the company.
Vanguard Group Inc. Has $128.25 Million Stake in Artivion, Inc. $AORT
Vanguard Group Inc. significantly increased its stake in Artivion, Inc. (NYSE: AORT) by 8.3% in the third quarter, now owning 3,029,059 shares valued at $128.25 million, representing 6.42% of the company. Despite this institutional confidence, key insiders, including CEO James P. Mackin, have recently sold a substantial number of shares. Analysts maintain a "Moderate Buy" rating for Artivion with a consensus price target of $48.97, following the company's recent beat on quarterly EPS and revenue estimates.
Artivion (AORT) CFO Lance Berry sells shares to cover RSU tax withholding
Artivion's CFO, Lance A. Berry, sold 5,178 shares of common stock at an average price of $38.0249 per share. This transaction was specifically to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) and was a non-discretionary "sell to cover" arrangement. After the sale, Berry directly holds 176,269 shares of Artivion common stock.
Artivion (AORT) CCO executes 2,784-share sell-to-cover tax sale
Artivion, Inc.'s Chief Commercial Officer, John E. Davis, reported an open-market sale of 2,784 shares of common stock at an average price of $38.0249 per share. This transaction was a non-discretionary "sell-to-cover" executed to satisfy tax withholding obligations related to the vesting of restricted stock units. After the sale, Davis directly holds 206,522 shares of Artivion common stock.
Tax-withholding share sale by Artivion (AORT) SVP Stanton Marshall
Artivion, Inc. Senior Vice President Stanton Marshall S. reported the automatic sale of 1,513 shares of common stock at an average price of $38.0249 per share. This sale was not a discretionary trade but occurred upon the vesting of restricted stock units, solely to cover tax withholding obligations. Following the transaction, Marshall directly holds 40,408 shares of Artivion common stock.
Holloway Jean F, Artivion SVP, sells $83k in shares
Artivion Inc.'s SVP, General Counsel Jean F. Holloway, sold 2,183 shares of common stock for $83,008 on March 2, 2026. This transaction was to cover tax withholding obligations related to restricted stock units rather than a discretionary sale. The company recently reported strong Q4 2025 earnings and revenue, though Canaccord Genuity lowered its price target due to market conditions.
Champlain Investment Partners LLC Takes Position in Artivion, Inc. $AORT
Champlain Investment Partners LLC has purchased 423,053 shares of Artivion, Inc. (NYSE:AORT) valued at approximately $17.9 million, representing about 0.90% ownership. This move comes despite recent insider selling, including by CEO James P. Mackin. Artivion beat its latest earnings estimates with $0.17 EPS and $118.3 million in revenue, while analysts maintain a "Moderate Buy" rating with an average target price of $48.97.
Artivion (NYSE: AORT) SVP gets stock award, sells shares for tax
Artivion (NYSE: AORT) Senior Vice President Stanton Marshall S. reported receiving 21,838 shares as a performance stock unit award and then selling 2,149 shares to cover tax withholding obligations. The sale was a non-discretionary "sell-to-cover" transaction. Following these transactions, Marshall directly owns 60,097 shares of Artivion common stock, with remaining portions of the award eligible to vest in 2027 and 2028.
Mackin James P, Artivion CEO, sells $566k in AORT stock
Artivion (NASDAQ:AORT) President and CEO James P. Mackin sold 14,911 shares of common stock for approximately $566,989 on March 2, 2026, to cover tax withholding obligations. This transaction leaves Mackin with 848,214 directly owned shares. Artivion's stock has seen a 53% return over the past year and the company reported strong Q4 2025 results, exceeding earnings expectations with an EPS of $0.17 and adjusted revenues of $118.3 million.
Artivion (NYSE:AORT) CEO Sells $566,916.22 in Stock
Artivion (NYSE:AORT) CEO James Mackin sold 14,911 shares of company stock for $566,916.22 on March 2nd, reducing his stake by 1.73%. The sale followed Artivion beating quarterly earnings estimates with an EPS of $0.17 and revenue of $118.3 million. The stock currently trades around $38.50 with analysts maintaining a "Moderate Buy" rating and an average target price of $48.97.
AORT | Artivion, Inc. Financials - Income Statement
This page provides financial and market data for Artivion, Inc. (AORT), including a summary of congressional trading activity, insider transactions, government contracts, and company information. It also details various financial metrics, analyst ratings, and the company's business segments.
How to watch Artivion's Oppenheimer MedTech fireside chat online
Artivion (NYSE: AORT) announced its virtual participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The company will host a fireside chat on March 17, 2026, at 9:20 a.m. ET, with a live webcast available on its Investors page and an archived copy accessible for 90 days. This participation continues Artivion's active communication around its aortic disease portfolio and follows recent positive financial and clinical updates.
Artivion: Chief commercial officer Davis sells $105k in shares
Artivion's Chief Commercial Officer, John E. Davis, sold 2,784 shares of company stock for $105,861 to cover tax obligations from vested restricted stock units. This transaction is not considered discretionary. Despite a strong 53% return over the past year, InvestingPro analysis indicates the shares may be overvalued.
ARTIVION CEO James P Mackin Sells Shares for Tax Obligations
ARTIVION's President & CEO, James P Mackin, recently sold 14,911 shares of Common Stock for a total of $566,989. This transaction was primarily to cover tax withholding obligations associated with vested restricted stock units. Following the sale, Mackin still directly owns 848,214 shares of ARTIVION.
Artivion, Inc. $AORT Position Trimmed by First Eagle Investment Management LLC
First Eagle Investment Management LLC reduced its stake in Artivion, Inc. (NYSE:AORT) by 18.0% in the third quarter, now owning 340,393 shares valued at approximately $14.41 million. Despite insider selling by CEO James P. Mackin and other insiders totaling over 73,089 shares in the last 90 days, Artivion recently beat quarterly EPS and revenue estimates, with revenue up 19.2% year-over-year. Wall Street analysts maintain a "Moderate Buy" rating with a consensus target price of $48.97, reflecting positive outlooks despite the mixed investor activity.
Artivion, Inc. (NYSE:AORT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Artivion, Inc. (NYSE:AORT) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $48.97. The company recently reported strong Q4 earnings, beating expectations with $0.17 EPS and 19.2% year-over-year revenue growth. Despite some insider selling, institutional ownership remains high, with significant stake increases from firms like Vanguard and Morgan Stanley.
